Stocks · Health care · Biological Products, (No Diagnostic Substances)

Voyager Therapeutics, Inc.

VYGR Clue Score26

United States Fiscal year ends December CIK 0001640266 Results filed 6 Aug 2026

Add to watchlist

What the insiders did Net buying

Individual transactions

Insider

Date

Role

Action

Price

Amount

Neurocrine Biosciences Inc

23 Feb 2023

10% owner

Buy

4,395,588

$8.88

$39.03M

EcoR1 Capital, LLC

23 Jun 2022

10% owner

Buy indirect

376,000

$5.66

$2.13M

EcoR1 Capital, LLC

21 Jun 2022

10% owner

Buy indirect

101,400

$5.28

$535.50K

Neurocrine Biosciences Inc

12 Mar 2019

10% owner

Buy

4,179,728

$11.96

$50.00M

Glenn Pierce

12 Sep 2018

Director

Buy indirect

5,000

$18.44

$92.20K

James A Geraghty

10 Sep 2018

Director

Buy

3,000

$19.39

$58.17K

James A Geraghty

17 Aug 2018

Director

Buy

3,000

$18.31

$54.93K

Show all 123 transactions →

What was left out

Form 4 filings counted 262

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 12

Sales on a Rule 10b5-1 plan 10

Sales straight out of an exercise 7

Sales at will 99

Transactions with no price 0

Shares from compensation/vesting 13,599,620

Sales filed before the plan box existed 67

History held since 18 Nov 2015